

List of Tables

Chapter 2

Table 2.1 Marketed formulation of SMEDDS.....	16
Table 2.2 Oils (Lipophilic phase) used in SMEDDS.....	17
Table 2.3 Examples of studies describing the effectiveness of SMEDDS formulations for poorly water-soluble drugs.....	21
Table 2.5 Recent research related to Niosomes	31
Table 2.6 Clinical Trials of niosomes.....	32
Table 2.7 Review of work done on ILO	38
Table 2.8 Review of work done on VDN	46

Chapter 3

Table 3.1 List of Excipients for formulation development.....	56
Table 3.2 List of Chemicals, Reagents and Filters used for Analysis	58
Table 3.3 Cell Line study useables	58
Table 3.4 Instruments used	59

Chapter 4

Table 4.1 Calibration data for ILO by UV in pH 6.8 phosphate buffer.....	69
Table 4.2 Calibration data for ILO by UV in pH 6.8 phosphate buffer.....	71
Table 4.3 Calibration data for ILO by HPLC	73
Table 4.4 Calibration data for ILO by UPLC-MS	76
Table 4.5 Calibration data for VDN by UV in pH 6.8 phosphate buffer.....	79
Table 4.6 Calibration data for VDN by UV in Acetonitrile	81
Table 4.7 Calibration data for VDN by HPLC	83
Table 4.8 Calibration data for VDN by UPLC-MS	86
Table 4.10 Area for Standard solution of chloroform – methanol mix obtained using HS-GC89	

Chapter 5

Table 5. 1 Variables for I-optimal design for optimization of ILO SMEDDS	95
Table 5.2 Variables for I-optimal design for optimization of SMEDDS.....	98
Table 5.3 Observation table for Dispersibility Study	101
Table 5.4 Process variables studied for niosomes formulation development.....	107
Table 5.5 Variables for Combined D-optimal Mixture design for optimization of niosomes	108

Chapter 6

ILO SMEDDS

Table 6.1 Selection of co-surfactant	121
Table 6.2 Three Component I-optimal design for optimization of ILO SMEDDS	123
Table 6.3 Model selection based on R ² value for I optimal design	125
Table 6.4 Optimized formulation composition.....	127
Table 6.5 Stability study results of ILO SMEDDS.....	140

VDN SMEDDS

Table 6.6 Selection of co-surfactant	143
Table 6.7 Three Component I-optimal design for optimization of VDN SMEDDS	147
Table 6.8 Model fit summary for globule size (Y1) of VDN SMEDDS	148
Table 6.9 Statistical Analysis for Globule Size (Y1).....	150
Table 6.10 Coefficient estimate for Globule size predictors	150
Table 6.11 Model fit summary for % transmittance (Y2)	152
Table 6.12 Statistical Analysis for % transmittance (Y2).....	153
Table 6.13 Coefficient estimate for % transmittance predictors.....	154
Table 6.14 Predicted and obtained responses for VDN SMEDDS prepared as per numerical optimization	156
Table 6.15 Stability study results of VDN SMEDDS	168

ILO Niosomes

Table 6.16 Method selection for ILO niosomes preparation	170
--	-----

Table 6.17 Risk Analysis by FMEA to identify criticality to potential failure causes for niosomes	174
Table 6.18 Effect of solvent evaporation time on thin film formation	175
Table 6.19 Optimization of rotation speed	177
Table 6.20 Effect of hydration time	178
Table 6.21 Effect of hydration volume	178
Table 6.22 Effect of Sonication cycles	179
Table 6.23 Optimized values of process parameters for Niosomes preparation.....	180
Table 6.24 design matrix for ILO Niosomes	181
Table 6.25 Coefficients in terms of coded factors for %EE predictors	182
Table 6.26 Statistical analysis for %EE.....	183
Table 6.27 Coefficients in terms of coded factors for size predictors	186
Table 6.28 Statistical analysis for Size	187
Table 6.29 Predicted and obtained responses for ILO Niosomes prepared as per numerical optimization	191

VDN Niosomes

Table 6.30 Design matrix for VDN Niosomes	193
Table 6.31 p-Value of coefficients for independent variables	200
Table 6.32 Predicted and obtained responses for VDN Niosomes prepared as per numerical optimization	201

Niosomes characterization

Table 6.33 Mean diameter (nm) measured by DLS technique	203
Table 6.34 FTIR characteristic peaks of ILO and VDN	209
Table 6.35 Stability study results of Niosomes	213

Chapter 7

Table 7.1 Optimised formulation composition of SMEDDS and Niosomes	220
--	-----

Chapter 8

Table 8.1 Groups of animals (Rats) for pharmacokinetic study	242
Table 8.2 Groups of animals (Mice) for pharmacodynamic study	243
Table 8.3 Groups of animals (Rats) for pharmacodynamic study	247
Table 8.4 Pharmacokinetic Parameters for ILO delivered orally as suspension, SMEDDS and Niosomes.....	250
Table 8.5 Pharmacokinetic Parameters for VDN delivered orally as suspension, SMEDDS and Niosomes.....	252